These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report. Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852 [TBL] [Abstract][Full Text] [Related]
11. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132 [TBL] [Abstract][Full Text] [Related]
13. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol. Colvin LA; Johnson PR; Mitchell R; Fleetwood-Walker SM; Fallon M J Clin Oncol; 2008 Sep; 26(27):4519-20. PubMed ID: 18802169 [No Abstract] [Full Text] [Related]
14. Perspective on the current use of bortezomib in multiple myeloma. San-Miguel J; Bladé J Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272 [No Abstract] [Full Text] [Related]
15. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks. Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098 [TBL] [Abstract][Full Text] [Related]
16. Cancer research. Taking garbage in, tossing cancer out? Garber K Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952 [No Abstract] [Full Text] [Related]
17. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma. Kenealy MK; Prince HM; Hönemann D Pharmacotherapy; 2006 Aug; 26(8):1205-6; discussion 1206. PubMed ID: 16863501 [No Abstract] [Full Text] [Related]
18. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936 [TBL] [Abstract][Full Text] [Related]
20. [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology]. Gotoh A; Ohyashiki K; Oshimi K; Usui N; Hotta T; Dan K; Ikeda Y; ; Rinsho Ketsueki; 2006 Dec; 47(12):1521-7. PubMed ID: 17233470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]